Industry Overview - Cannabis stocks experienced a downturn for a second consecutive day despite President Trump's consideration of an executive order to loosen marijuana regulations [1] - The Amplify Seymour Cannabis ETF (CNBS) saw a significant drop of nearly 7% after a previous surge of over 50% on Friday, indicating profit-taking by investors [2] Regulatory Changes - President Trump indicated that he is "considering" an executive order to reclassify marijuana, which could lead to increased research opportunities [2] - Reports suggest that the reclassification would move marijuana from a Schedule I substance to a Schedule III drug, aligning it with less regulated substances like steroids and Tylenol with codeine [3] Market Sentiment - The cannabis sector experienced a rally on Friday, marking the Amplify Seymour fund's best day on record and putting it on track to end a four-year losing streak [3] - Industry insiders express optimism about the potential for regulatory changes to attract banks and large investors to the cannabis sector, with Tilray's CEO noting increased optimism [4] - Despite the overall positive sentiment, major cannabis producers like Tilray and Canopy Growth saw declines of 10% and 4.6%, respectively, while retailer SNDL dropped over 13% on Monday [4]

Core Point - President Donald Trump is considering signing an executive order to reclassify marijuana as a less dangerous drug [1] Group 1 - The potential reclassification of marijuana could impact its legal status and accessibility [1] - This move may influence the cannabis industry, potentially leading to increased investment and market growth [1] - The decision reflects a shift in the government's approach to drug policy, which could have broader implications for public health and safety [1]

Core Viewpoint - Cannabis stocks experienced a significant surge following reports that President Trump is preparing to reclassify marijuana under federal law, which could ease restrictions and revitalize the industry [1][8]. Industry Impact - The rally represents one of the largest single-day increases for cannabis stocks in years, breaking a prolonged slump that had left many stocks trading at a fraction of their 2021 highs [2][11]. - Reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act would acknowledge its medical use and reduce federal barriers that have hindered cannabis companies for years [8][14]. Company Performance - Tilray Brands saw a notable increase, trading at $11.85, up $3.42 or over 40%, although it remains below its 52-week high of $23.20 [4]. - Canopy Growth rose approximately 50% to around $1.70 per share, with trading volume exceeding 117 million shares [5]. - Curaleaf increased by 38% to $3.71 per share, while Aurora Cannabis climbed nearly 18% to about $5.35 per share [5]. Market Indicators - The AdvisorShares Pure US Cannabis ETF, a key indicator for the domestic cannabis industry, jumped more than 50% to around $5.71, nearing its 52-week high of $6.02 after being around $2 earlier this year [5]. - Despite the recent surge, broad cannabis indices remain down over 90% from their pandemic-era peaks, indicating ongoing volatility in the sector [11]. Regulatory Context - Current federal law classifies marijuana as a Schedule I drug, placing it alongside substances like heroin and LSD [6]. - Schedule III status would facilitate medical research, allow cannabis businesses to deduct ordinary expenses, and improve access to banking and institutional capital [9][14]. - Any reclassification would require a rulemaking process involving agencies such as the Drug Enforcement Administration, and no final decisions have been made yet [12]. Investor Sentiment - The sustainability of the recent rally depends on whether Trump will issue a formal order and the speed of regulatory changes [15]. - The surge in cannabis stocks marks a rare moment of optimism for an industry that has faced significant challenges over the past three years [15].

Core Viewpoint - President Trump is reportedly considering an order to reschedule marijuana from a Schedule I to a Schedule III drug, which could significantly impact the cannabis industry by allowing companies to access banking services and reducing tax burdens [1][2][3] Industry Impact - Rescheduling marijuana would not legalize it but would allow cannabis companies to operate more freely, potentially leading to a different tax status, reducing tax rates from approximately 40% to around 10-15% [3][9] - The cannabis market is currently experiencing volatility, with some stocks, like MISO, seeing increases of up to 38% due to speculation around this potential order [5][13] Regulatory Process - The Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) are expected to restart the rulemaking process for rescheduling, which is about 70% complete and could be finalized by the first half of next year if expedited [6][17] - There is uncertainty regarding the specifics of the order, as it may face legal challenges if it does not provide clear directives for rescheduling [7][9] Market Sentiment - Retail sentiment is currently high in the cannabis market, with Canadian pot equities also seeing increases of around 30%, although this does not directly apply to U.S. companies [13][14] - The potential for consolidation in the cannabis industry is anticipated as regulatory frameworks improve, with larger companies likely to acquire smaller ones [16][18]

Core Viewpoint - The potential reclassification of marijuana by President Trump could significantly impact Aurora Cannabis and the broader marijuana industry, making it easier for businesses to operate and increasing demand for cannabis products [3][4]. Group 1: Legislative Changes - President Trump is expected to issue an executive order to reclassify marijuana from Schedule I to Schedule III, which could occur as early as January [3]. - This reclassification would not legalize marijuana outright but would facilitate business operations within the industry, aligning cannabis more closely with prescription drugs [3]. Group 2: Financial Implications - The reclassification would likely lead to banks being more willing to extend loans and accept deposits from marijuana businesses, enhancing the financial landscape for companies like Aurora Cannabis [4]. - Companies would also benefit from being able to deduct more expenses from their income taxes, potentially increasing legal demand for marijuana products [4]. Group 3: Market Performance - Aurora Cannabis stock experienced a significant increase of 14.5% following the positive news regarding marijuana legalization [1]. - Despite the optimistic market reaction, Aurora Cannabis has struggled with profitability, continuing to report losses even in a legal market like Canada since 2018 [6][7].

Core Viewpoint - Cannabis stocks, including Tillray and Aurora, are experiencing significant gains due to reports that the president plans to reclassify marijuana to a less dangerous category, potentially moving it from Schedule I to Schedule III, similar to Tylenol with codeine [1][2] Group 1: Reclassification Process - The president is reportedly drafting an executive order to advise the DOJ and DEA to proceed with the reclassification, which could be issued as soon as Monday [2] - Following the executive order, the DOJ and DEA will publish a final rule, which will then enter a 30-day waiting period for any challenges, indicating potential delays due to opposition [4] Group 2: Industry Perspectives - Tillray's CEO, Irwin Simon, expresses optimism about the reclassification, believing that there will be significant changes by the end of the year, marking a departure from previous false starts [3] - A cannabis lawyer suggests that this reclassification could signal the beginning of a new era in public health policy, although it is viewed as a partial victory with ongoing legalization and regulatory challenges ahead [5] Group 3: Implications of Reclassification - The reclassification is not equivalent to legalization but is expected to facilitate medical research on cannabis, which could lead to broader acceptance and potential future legalization at the federal level [6][8] - The industry hopes that increased medical use will eventually pave the way for more recreational cannabis products, especially in light of recent legislative actions like the hemp ban [8]

Core Insights - US-listed cannabis stocks experienced significant premarket gains on Friday due to reports indicating a potential shift in federal marijuana policy under President Donald Trump [1] Group 1: Market Reaction - The cannabis sector saw a revival in investor interest following the news of possible changes in federal policy [1] - The premarket gains suggest a positive market sentiment towards cannabis stocks amid the evolving regulatory landscape [1]

Core Insights - Aurora Cannabis Inc. has launched a new proprietary cultivar named Black Jelly in Poland, enhancing its portfolio of high-potency medical cannabis products in a rapidly growing European market [1][2] - Black Jelly features a cannabinoid profile of THC 27% and CBD <1%, and is derived from a high-THC sativa strain [2] - The company emphasizes its advanced genetic breeding program and cultivation excellence as key factors in successfully introducing this product to the Polish market [2][3] Product Details - Black Jelly is characterized by dense, large flowers with green and orange hues, and a terpene profile that includes sweet black liquorice and fruity undertones [2] - The product is grown and manufactured in Aurora's Canadian facilities that are certified under GACP and EU-GMP standards [1][2] Market Position - Aurora Cannabis continues to strengthen its leadership in the international medical cannabis sector, leveraging scientific expertise and regulatory knowledge to support patient access and market growth across Europe [3] - The company has over a decade of experience in global medical markets, positioning itself as a trusted partner in advancing Poland's medical cannabis ecosystem [3] Company Overview - Aurora Cannabis operates in both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a diverse brand portfolio [4] - The company also holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants in North America [5]

Thank you everybody for being here. Are we good. Uh the organizers asked me to come in and talk a little bit about my journey that I like to call farm to photonix.You can drop the the fancy slogan there. I just put that on there. Um in the hope that potentially I can inspire others to kind of forge new paths and and just dream big and and and you know do great things, right. If anything, some of the lessons learned that I'm going to talk about through this slide deck, um, hopefully you can employ those in y ...

Here Is How Reform Will Help Most Marijuana Stocks In The MarketWith 2026 showing to be a big year for reform, how will this impact marijuana stocks? Looking back over the years, it is clear that marijuana stocks have seen their best trading when positive news on reform is released. The speculation of what could happen drives the market action up often. If investors feel the reform is important enough, you’ll then see some increased buying action.What many know already is the long, grueling, intense volatil ...